CY1122563T1 - ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt - Google Patents

ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt

Info

Publication number: CY1122563T1
Authority: CY; Cyprus
Prior art keywords: amide substituted; substituted thiazoles; compound; rorγt modulators; rorγt
Prior art date: 2014-10-30

Application number

CY20201100049T

Other languages

Greek (el)

English (en)

Inventor

Hariharan Venkatesan

Virginia TANIS

Maud Urbanski

Aihua Wang

David Kummer

Christoph Steeneck

Christian Gege

Olaf Kinzel

Gerald Kleymann

Thomas Hoffmann

Steven Goldberg

Anne M. Fourie

Xiaohua XUE

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-30

Filing date

2020-01-21

Publication date

2021-01-27

2020-01-21 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

2021-01-27 Publication of CY1122563T1 publication Critical patent/CY1122563T1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Thiazole And Isothizaole Compounds (AREA)

CY20201100049T 2014-10-30 2020-01-21 ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt CY1122563T1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462072599P	2014-10-30	2014-10-30
PCT/US2015/058200 WO2016069978A1 (en)	2014-10-30	2015-10-30	AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT

Publications (1)

Publication Number	Publication Date
CY1122563T1 true CY1122563T1 (el)	2021-01-27

Family

ID=54542554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20201100049T CY1122563T1 (el)	2014-10-30	2020-01-21	ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt

Country Status (21)

Country	Link
US (1)	US9845319B2 (es)
EP (1)	EP3212642B1 (es)
JP (1)	JP6695335B2 (es)
KR (1)	KR20170075787A (es)
CN (1)	CN108064224B (es)
AU (1)	AU2015339091B2 (es)
BR (1)	BR112017008852A2 (es)
CA (1)	CA2965518A1 (es)
CY (1)	CY1122563T1 (es)
DK (1)	DK3212642T3 (es)
ES (1)	ES2767303T3 (es)
HK (1)	HK1243418A1 (es)
HR (1)	HRP20200016T1 (es)
HU (1)	HUE046888T2 (es)
IL (1)	IL251857B (es)
MA (1)	MA40865B1 (es)
PL (1)	PL3212642T3 (es)
PT (1)	PT3212642T (es)
RS (1)	RS59752B1 (es)
SI (1)	SI3212642T1 (es)
WO (1)	WO2016069978A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20200117A1 (ar)	2014-10-30	2017-06-16	Janssen Pharmaceutica Nv	كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
SI3212641T1 (sl)	2014-10-30	2019-02-28	Janssen Pharmaceutica Nv	Tiazoli kot modulatorji RORyt
TW201803869A (zh) *	2016-04-27	2018-02-01	健生藥品公司	作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN112292124A (zh) *	2018-03-12	2021-01-29	爱思凯利尔生物科学私人有限责任公司	双环ROR-γ调节剂
KR20210060367A (ko)	2018-03-12	2021-05-26	에스칼리에 바이오사이언시스, 비브이	스피로사이클릭 ror-감마 조절제
WO2019243965A1 (en) *	2018-06-18	2019-12-26	Janssen Pharmaceutica Nv	Pyrazole derivatives as malt1 inhibitors
JP2021528398A (ja)	2018-06-18	2021-10-21	ヤンセンファーマシューティカエヌ．ベー．	ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール
CA3103932A1 (en)	2018-06-18	2019-12-26	Janssen Pharmaceutica Nv	Pyridinyl pyrazoles as modulators of roryt
CA3103770A1 (en)	2018-06-18	2019-12-26	Janssen Pharmaceutica Nv	Phenyl and pyridinyl substituted imidazoles as modulators of roryt
WO2019243999A1 (en)	2018-06-18	2019-12-26	Janssen Pharmaceutica Nv	Phenyl substituted pyrazoles as modulators of roryt

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL91418A (en)	1988-09-01	1997-11-20	Rhone Poulenc Agrochimie	(hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
JPH10504542A (ja)	1994-07-27	1998-05-06	ジー．ディー．サールアンドカンパニー	炎症処置用の置換チアゾール化合物
BR0208956A (pt)	2001-04-16	2004-07-13	Tanabe Seiyaku Co	Abridor de canais de k ativados por cálcio de grande condutância
PL210475B1 (pl) *	2001-08-13	2012-01-31	Janssen Pharmaceutica Nv	Pochodna 2,4,5-tripodstawionego tiazolilu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
EP1435951B1 (en) *	2001-10-12	2006-01-18	Bayer Pharmaceuticals Corporation	Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
WO2006124687A1 (en)	2005-05-12	2006-11-23	University Of Medicine And Dentistry Of New Jersey	Opioid receptor subtype-selective agents
AU2007208225B2 (en)	2006-01-25	2013-05-02	Synta Pharmaceuticals Corp.	Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064318A2 (en)	2006-11-22	2008-05-29	University Of Medicine And Dentistry Of New Jersey	Peripheral opioid receptor active compounds
WO2008064317A1 (en)	2006-11-22	2008-05-29	University Of Medicine And Dentistry Of New Jersey	Lipophilic opioid receptor active compounds
US20090069288A1 (en)	2007-07-16	2009-03-12	Breinlinger Eric C	Novel therapeutic compounds
AU2009270520A1 (en)	2008-07-17	2010-01-21	Bayer Cropscience Ag	Heterocyclic compounds used as pesticides
AR079022A1 (es)	2009-11-02	2011-12-21	Sanofi Aventis	Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011112264A1 (en)	2010-03-11	2011-09-15	New York University	Compounds as rorϒt modulators and uses thereof
EP3002008B8 (en)	2010-03-11	2018-10-24	New York University	Amido compounds as roryt modulators and uses thereof
WO2011115892A1 (en)	2010-03-15	2011-09-22	Griffin Patrick R	Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en)	2010-09-01	2012-03-08	Glaxo Group Limited	Novel compounds
US9505798B2 (en)	2010-11-29	2016-11-29	New York University	Steroid compounds as RORyt modulators and uses thereof
WO2012090995A1 (ja)	2010-12-28	2012-07-05	ライオン株式会社	口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム
WO2012129491A1 (en)	2011-03-24	2012-09-27	Abbott Laboratories	Trpv3 modulators
US9586928B2 (en)	2011-05-16	2017-03-07	The Scripps Research Institute	Modulators of the nuclear hormone receptor ROR
JP6054869B2 (ja)	2011-07-29	2016-12-27	武田薬品工業株式会社	複素環化合物
JP2014528933A (ja)	2011-09-09	2014-10-30	ニューヨークユニバーシティ	ＲＯＲγｔモジュレーターとしてのアミド化合物およびその使用
WO2013079223A1 (en)	2011-12-02	2013-06-06	Phenex Pharmaceuticals Ag	Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en)	2011-12-22	2013-07-25	Genentech, Inc.	Benzyl sulfonamide derivatives as rorc modulators
SG11201407919WA (en) *	2012-05-31	2014-12-30	Phenex Pharmaceuticals Ag	Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
CN105705501B (zh)	2013-09-09	2019-04-19	百时美施贵宝公司	RORγ调节剂
US20150072890A1 (en)	2013-09-11	2015-03-12	20/20 Gene Systems, Inc.	Methods and compositions for aiding in the detection of lung cancer
JP6397488B2 (ja)	2013-09-20	2018-09-26	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	ＲＯＲγ調節因子
PL3077372T3 (pl)	2013-12-05	2019-09-30	Lead Pharma Holding B.V.	MODULATORY ROR GAMMA (RORγ)
US9708253B2 (en)	2014-01-06	2017-07-18	Bristol-Myers Squibb Company	Cyclohexyl sulfone RORγ modulators
ES2705400T3 (es)	2014-01-06	2019-03-25	Bristol Myers Squibb Co	Sulfonas heterocíclicas como moduladores de ROR gamma
TW201609634A (zh)	2014-01-06	2016-03-16	必治妥美雅史谷比公司	吡咯啶基碸類視色素相關孤兒受體γ（ＲＯＲγ）調節劑
CN106132931B (zh)	2014-01-06	2019-08-02	百时美施贵宝公司	碳环砜RORγ调节剂
AU2015237788B2 (en)	2014-03-27	2021-03-11	Piramal Enterprises Limited	ROR-gamma modulators and uses thereof
CN103833672A (zh) *	2014-03-28	2014-06-04	中国药科大学	一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法

2015
- 2015-10-30 CA CA2965518A patent/CA2965518A1/en not_active Abandoned
- 2015-10-30 KR KR1020177014656A patent/KR20170075787A/ko not_active Application Discontinuation
- 2015-10-30 MA MA40865A patent/MA40865B1/fr unknown
- 2015-10-30 RS RS20191697A patent/RS59752B1/sr unknown
- 2015-10-30 JP JP2017523349A patent/JP6695335B2/ja not_active Expired - Fee Related
- 2015-10-30 BR BR112017008852-5A patent/BR112017008852A2/pt not_active Application Discontinuation
- 2015-10-30 US US14/927,502 patent/US9845319B2/en active Active
- 2015-10-30 ES ES15794729T patent/ES2767303T3/es active Active
- 2015-10-30 PL PL15794729T patent/PL3212642T3/pl unknown
- 2015-10-30 HU HUE15794729A patent/HUE046888T2/hu unknown
- 2015-10-30 EP EP15794729.2A patent/EP3212642B1/en active Active
- 2015-10-30 CN CN201580072012.8A patent/CN108064224B/zh not_active Expired - Fee Related
- 2015-10-30 AU AU2015339091A patent/AU2015339091B2/en not_active Ceased
- 2015-10-30 DK DK15794729T patent/DK3212642T3/da active
- 2015-10-30 SI SI201530992T patent/SI3212642T1/sl unknown
- 2015-10-30 WO PCT/US2015/058200 patent/WO2016069978A1/en active Application Filing
- 2015-10-30 PT PT157947292T patent/PT3212642T/pt unknown
2017
- 2017-04-23 IL IL251857A patent/IL251857B/en not_active IP Right Cessation
2018
- 2018-03-02 HK HK18103051.0A patent/HK1243418A1/zh unknown
2020
- 2020-01-07 HR HRP20200016TT patent/HRP20200016T1/hr unknown
- 2020-01-21 CY CY20201100049T patent/CY1122563T1/el unknown

Also Published As

Publication number	Publication date
PT3212642T (pt)	2019-12-19
BR112017008852A2 (pt)	2018-01-16
MA40865B1 (fr)	2019-11-29
CA2965518A1 (en)	2016-05-06
EP3212642B1 (en)	2019-10-30
WO2016069978A1 (en)	2016-05-06
CN108064224B (zh)	2022-03-29
CN108064224A (zh)	2018-05-22
HK1243418A1 (zh)	2018-07-13
AU2015339091A1 (en)	2017-05-11
IL251857A0 (en)	2017-06-29
US9845319B2 (en)	2017-12-19
US20160122335A1 (en)	2016-05-05
JP6695335B2 (ja)	2020-05-20
AU2015339091B2 (en)	2020-05-28
IL251857B (en)	2020-09-30
ES2767303T3 (es)	2020-06-17
RS59752B1 (sr)	2020-02-28
HRP20200016T1 (hr)	2020-03-20
HUE046888T2 (hu)	2020-03-30
DK3212642T3 (da)	2019-11-25
KR20170075787A (ko)	2017-07-03
PL3212642T3 (pl)	2020-04-30
EP3212642A1 (en)	2017-09-06
JP2018500286A (ja)	2018-01-11
SI3212642T1 (sl)	2020-01-31

Publication	Publication Date	Title
CY1122563T1 (el)	2021-01-27	ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt
CY1119234T1 (el)	2018-02-14	Μεθυλενο συνδεδεμενοι κινολινυλ ρυθμιστες του ror-γαμμα-τ
CY1121716T1 (el)	2020-07-31	Τριφθορομεθυλο αλκοολες ως διαμορφωτες της ror-γαμμα-τ
CY1121285T1 (el)	2020-05-29	Θειαζολια ως διαμορφωτες toy roryt
CY1125214T1 (el)	2023-06-09	Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123569T1 (el)	2022-03-24	Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer
CY1122821T1 (el)	2021-05-05	Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1124476T1 (el)	2022-07-22	Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1124496T1 (el)	2022-07-22	Οξυστερολες και μεθοδοι χρησης αυτων
BR112018070602A2 (pt)	2019-02-05	composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
EA201890308A1 (ru)	2018-08-31	Замещенные азасоединения как ингибиторы irak-4
CY1120325T1 (el)	2019-07-10	Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης
CY1122916T1 (el)	2021-10-29	Νεες ενωσεις ως ρυθμιστες ror γαμμα
CY1125963T1 (el)	2024-09-20	Ρυθμιστες υποδοχεα ρ2χ3 και ρ2χ2/3 διαμινοπυριμιδινης για χρηση στη θεραπεια βηχα
CY1124929T1 (el)	2023-01-05	4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139
GT201500092A (es)	2015-12-31	Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
CY1120111T1 (el)	2018-12-12	Αντιβακτηριακα παραγωγα 2η-ινδαζολης
CY1121362T1 (el)	2020-05-29	Παραγωγα της 1,2-διϋδρο-3η- πυρρολo[1,2-c] ιμιδαζολ-3-ονης και η χρηση τους ως αντιβακτηριακοι παραγοντες
ECSP18088146A (es)	2018-11-30	6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT
BR112016008258A2 (pt)	2017-10-10	moduladores de ror?t de quinolinila
UY36263A (es)	2016-02-29	Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
EA201790327A1 (ru)	2017-10-31	Соединения замещенного пиперидина
EA201691412A1 (ru)	2016-12-30	Гидроксиформамидные производные и их применение
CY1120875T1 (el)	2019-12-11	Ν-(ετερο)αρυλ-υποκατασταθεντα ετεροκυκλικα παραγωγα χρησιμα για την αγωγη νοσων ή παθησεων που σχετιζονται με το κεντρικο νευρικο συστημα
CY1119496T1 (el)	2018-03-07	Θεραπευτικος παραγοντας για ασθενεια που βασιζεται στην ανασταλτικη δραση στον παραγοντα αναστολης της μεταναστευσης μακροφαγων